Genmab — Juli 2020
-
Med efterfølgende mulighed for brud af 3.000.
-
-
Genmab initiated with a Sell at Societe Generale Societe Generale analyst Justin Smith initiated coverage of Genmab with a Sell rating and DKK 1,620 price target. While Smith acknowledges that 2019 was the seventh consecutive year of profitability and projects "a six-fold expansion" in annual sales from 2019-2030, he does not believe that the current share price appropriately discounts the company's portfolio concentration risk.
Read more at:
https://thefly.com/landingPageNews.php?id=3120375 -
En af verdens førende kriminelle banker med bånd til den gamle kommunistiske, fascistiske Soros der vil have NWO indført. Blev nationaliseret i 45 og privatiseret igen i 1987. Er anklaget for masser af ulovligheder som er typisk for elitens banker der malker de intetanende borgere der godtroende tror på deres politikere som nærmest har et symbiotisk bånd til pengebagmændene, de ægte kriminelle der suger al næring ud af middelklassen.https://en.wikipedia.org/wiki/Société_Génér
-
En "kommende" folkeaktie. Det er altså en ommer Mcjean.
-
nohope..Du lever op til dit navn. Genmab er altså en etableret "proletaraktie".
-
God morgen.
-
"Kursmålet er samtidig fastsat til 1620 kr. Dermed venter finanshuset, at aktien vil falde omkring 27 pct. fra det nuværende kursniveau, skriver Bloomberg News.
Kun 4 af 27 analytikere, der leverer analyser til Bloomberg, anbefaler sælg, mens 14 anbefaler køb."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind